Dissemination of a reliable and valid family maltreatment determination model: 33-site, system-wide replication and extension of Heyman and Slep (2009a).

The need for standardized criteria in partner and child maltreatment response systems is critical for providing fair decisions, allocating family support, producing reliable research findings, and aiding prevention efforts, among other tasks. The primary goal of this study was to replicate Heyman and Slep's (see record 2009-23534-017) study-whether maltreatment incident determination committee decisions of local sites matched those of master reviewers. This study extended the prior work by testing if specific training techniques (i.

Afraid of the dentist? There's an app for that: Development and usability testing of a cognitive behavior therapy-based mobile app.

Objectives: Although several brief cognitive behavior therapy (CBT)-based treatments for dental fear have proven efficacious, these interventions remain largely unavailable outside of the specialty clinics in which they were developed. Leveraging technology, we sought to increase access to treatment for individuals with dental fear through the development of a mobile application (Dental FearLess).

Materials And Methods: To assess the resonance of our app as an avenue for dental fear treatment, we conducted a study assessing the usability, feasibility, and acceptability of the beta app.

Socioeconomic Status and Major Adverse Transplant Events in Pediatric Heart Transplant Recipients.

Importance: Low socioeconomic status (SES) has been associated with higher risk of rejection and graft loss in pediatric heart transplant (HT) recipients. The association of SES with other posttransplant morbidities is unknown.

Objective: To assess whether low SES is associated with higher risk of a major adverse transplant event (MATE) among pediatric HT recipients.

Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.

Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).